
Taking chemotherapy directly to skin lesions, with Dr Raza B...
At BIO 2025 in Boston, editor-in-chief Jonah Comstock spoke with Dr Raza Bokhari, CEO of Medicus Pharma.
Newsletters and Deep Dive digital magazine
At BIO 2025 in Boston, editor-in-chief Jonah Comstock spoke with Dr Raza Bokhari, CEO of Medicus Pharma.
FDA advisors have voted that the benefit/risk profile of GSK's multiple myeloma therapy, Blenrep, does not support its approval in the US.
Novartis' breast cancer therapy Kisqali has been cleared for NHS use in early breast cancer, an indication driving blockbuster sales of the drug.
Mark Wildgust, VP of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, discusses J&J’s ambition to get in front of cancer.
LaNova Medicines is being bought out by minority shareholder Sino Biopharm in a deal valued at around $951 million.
Editor's Picks
Newsletters and Deep Dive
digital magazine